Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.
Matthew R BrierSuzanne E SchindlerSalter AmberDana PerantieNicole ShelleyBradley JudgeSarah J KeefeKristopher M KirmessPhilip B VergheseKevin E YarasheskiVenky VenkateshCyrus A RajiBrian A GordonRandall J BatemanJohn C MorrisRobert T NaismithDavid M HoltzmanTammie L S BenzingerAnne H CrossPublished in: Annals of neurology (2024)
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.